Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment

The Soft Tissue Sarcoma market is rapidly evolving with cutting-edge research and breakthrough therapies driven by leading companies like Sun Yat-sen University, QBiotics Group Limited, and Thermosome GmbH. These innovators are revolutionizing treatment approaches and shaping the future of soft tissue Sarcoma care, offering new hope for patients worldwide.

DelveInsight's 'Soft Tissue Sarcoma Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Soft Tissue Sarcoma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Soft Tissue Sarcoma pipeline domain.

For emerging Soft Tissue Sarcoma drugs, the Soft Tissue Sarcoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Soft Tissue Sarcoma Pipeline Report
• DelveInsight's Soft Tissue Sarcoma Pipeline analysis depicts a robust space with 70+ active players working to develop 75+ pipeline drugs for Soft Tissue Sarcoma treatment.
• The leading Soft Tissue Sarcoma companies include Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics, and others are evaluating their lead assets to improve the Soft Tissue Sarcoma treatment landscape.
• Key Soft Tissue Sarcoma pipeline therapies in various stages of development include Fibronum + Doxorubicin, Chiauranib, LVGN6051 and Anlotinib, Chiauranib, AVA6000, LOXO-292, HFB301001, ADI PEG20, Tigilanol Tiglate, and others.
• In December 2024, EpicentRx announced that the FDA granted Fast Track designation to AdAPT-001, an oncolytic adenovirus-delivered transforming growth factor beta (TGFβ) inhibitor, in combination with either the anti-PD-1 drug nivolumab or the anti-PD-L1 drug atezolizumab, for treating recurrent or refractory advanced or metastatic soft tissue sarcoma (STS) with disease progression following at least one prior therapy.
• In September 2024, Actuate Therapeutics, Inc. announced that the FDA has granted an Orphan Drug Designation to elraglusib, a novel GSK-3β inhibitor. This designation is for treating soft tissue sarcoma (STS), a rare and challenging cancer involving malignant tumors in the connective tissues, such as muscles, fat, and nerves. This designation highlights the potential of elraglusib to address a significant unmet need in treating this high-impact cancer.

Request a sample and discover the recent breakthroughs happening in the Soft Tissue Sarcoma pipeline landscape @ https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Soft Tissue Sarcoma Overview
Soft tissue sarcomas (STS) are a rare and diverse group of malignant tumors that develop in the body's soft tissues, including muscles, fat, nerves, blood vessels, and tendons. While they account for less than 1% of adult cancers, they are more prevalent in children, comprising about 7% of pediatric cancers. With over 50 subtypes, these tumors can appear anywhere in the body, though they most commonly occur in the limbs and abdomen. In the early stages, STS may not present noticeable symptoms, making early detection challenging. As tumors grow, they can cause a visible lump, pain, or discomfort, especially if they press on nerves or muscles. Abdominal sarcomas may lead to digestive issues, a feeling of fullness, or persistent pain, while advanced disease can result in systemic symptoms like fatigue and weight loss.

The exact cause of STS remains unclear, though genetic predispositions, exposure to certain chemicals, and prior radiation therapy have been identified as risk factors. Many soft tissue sarcomas are linked to specific genetic mutations and chromosomal translocations that drive uncontrolled cell growth. Diagnosis typically involves imaging techniques such as MRI, CT, or PET scans to assess tumor size and spread, followed by a biopsy to confirm the type of sarcoma. Treatment strategies vary based on tumor type, stage, and location, with surgery being the primary approach, often combined with radiation therapy to reduce recurrence risk. Chemotherapy is used for aggressive or metastatic cases, while emerging targeted therapies and immunotherapies offer new hope in specific subtypes. A multidisciplinary treatment approach is essential for improving patient outcomes and managing this complex disease.

Find out more about Soft Tissue Sarcoma medication @ https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Soft Tissue Sarcoma Treatment Analysis: Drug Profile
Fibronum + Doxorubicin: Philogen S.p.A.
Fibromun (L19TNF) is a fully human immunomodulatory product combining the L19 antibody with TNF, a potent pro-inflammatory cytokine. (Recombinant TNF has been approved for specific clinical uses.) The fusion of TNF with the L19 antibody, which targets the EDB domain of fibronectin, creates a tumor-targeted treatment that selectively concentrates at the disease site while sparing healthy tissues. Fibromun has demonstrated strong anti-tumor effects, both as a single agent and in combination with other drugs, in various immunocompetent preclinical models, often leading to long-lasting complete responses. The drug is currently in Phase III development for treating Soft Tissue Sarcoma.

Chiauranib: Chipscreen Biosciences, Ltd
Chiauranib, developed by Chipscreen Biosciences, is a highly selective inhibitor targeting Aurora B, VEGFR, PDGFR, c-Kit, and CSF1R, designed to overcome drug resistance. It works through a triple-pathway mechanism, inhibiting tumor angiogenesis, preventing tumor cell mitosis, and modulating the tumor microenvironment. With a favorable safety profile, Chiauranib has shown superior pharmacodynamic activity in animal studies compared to similar drugs. The drug is currently in Phase II development for treating Soft Tissue Sarcoma.

Key Soft Tissue Sarcoma Therapies and Companies
• Fibronum + Doxorubicin: Philogen S.p.A.
• Chiauranib: Chipscreen Biosciences, Ltd
• LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited
• Chiauranib: Chipscreen Biosciences, Ltd.
• Tigilanol Tiglate: QBiotics Group Limited
• ADI PEG20: Polaris Group
• HFB301001: HiFiBiO Therapeutics
• LOXO-292: Eli Lilly and Company
• AVA6000: Avacta Life Sciences Ltd

Learn more about the novel and emerging Soft Tissue Sarcoma pipeline therapies @ https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Soft Tissue Sarcoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Soft Tissue Sarcoma Pipeline Report
• Coverage: Global
• Key Soft Tissue Sarcoma Companies: Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics, and others.
• Key Soft Tissue Sarcoma Pipeline Therapies: Fibronum + Doxorubicin, Chiauranib, LVGN6051 and Anlotinib, Chiauranib, AVA6000, LOXO-292, HFB301001, ADI PEG20, Tigilanol Tiglate, and others.

Dive deep into rich insights for drugs used for Soft Tissue Sarcoma treatment; visit @ https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Soft Tissue Sarcoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Soft Tissue Sarcoma Pipeline Therapeutics
6. Soft Tissue Sarcoma Pipeline: Late-Stage Products (Phase III)
7. Soft Tissue Sarcoma Pipeline: Late-Stage Products (Phase III)
8. Soft Tissue Sarcoma Pipeline: Mid-Stage Products (Phase II)
9. Soft Tissue Sarcoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.